Skip to content

Franz X. Vollenweider

University Hospital Zurich, University of Zurich

111 papers in the library · 13,546 citations · publishing 1997-2026

Papers

Sort Most recent Most cited

The neurobiology of psychedelic drugs: implications for the treatment of mood disorders.

Nature Reviews Neuroscience September 2010 Franz X. Vollenweider, Michael Kometer

After a pause of nearly 40 years in research into the effects of psychedelic drugs, recent advances in our understanding of the neurobiology of psychedelics, such as lysergic acid diethylamide (LSD), psilocybin and ketamine have led to renewed interest in the clinical potential of psychedelics in the treatment of various psychiatric disorders. Recent behavioural and neuroimaging data show that...

Psychometric Evaluation of the Altered States of Consciousness Rating Scale (OAV)

PLoS One August 31, 2010 Erich Studerus, Alex Gamma, Franz X. Vollenweider 693 citations

The original scales of the OAV were shown to be multidimensional constructs. Eleven new lower order scales were constructed and demonstrated to have desirable psychometric properties. The new lower order scales are most likely better suited to assess drug induced ASC.

DOI: 10.1371/journal.pone.0012412 (opens in new tab) Rating scale Scale ratio Psychometrics Clinical psychology +2

Psilocybin slows binocular rivalry switching through serotonin modulation

Journal of Vision March 19, 2010 Olivia Carter, John D. Pettigrew, Felix Hasler et al. 3 citations

Binocular rivalry refers to the fluctuations in visual awareness/suppression that occur when different images are simultaneously presented to each eye. To explore the role of serotonin (5-HT) in binocular rivalry, this study investigated the affects of the hallucinogenic 5-HT1A&2A receptor agonist psilocybin (the active compound in “magic mushrooms”), alone and after pretreatment with the...

Using psilocybin to investigate the relationship between attention, working memory and the serotonin 5-HT1A and 5-HT2A receptors

Journal of Vision March 17, 2010 Olivia Carter, David C. Burr, John D. Pettigrew et al. 6 citations

Increasing evidence suggests a link between attention, working memory, serotonin (5-HT) and prefrontal cortex activity. In an attempt to tease out the relationship between these elements, this study tested the effects of the hallucinogenic 5-HT1A/2A receptor agonist psilocybin alone and after pretreatment with the 5-HT2A antagonist ketanserin on multiple object tracking and spatial working...

Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists

The World Journal of Biological Psychiatry March 1, 2010 Patrik Roser, Franz X. Vollenweider, Wolfram Kawohl 63 citations

Delta(9)-Tetrahydrocannabinol (Delta(9)-THC), the principal psychoactive constituent of the Cannabis sativa plant, and other agonists at the central cannabinoid (CB(1)) receptor may induce characteristic psychomotor effects, psychotic reactions and cognitive impairment resembling schizophrenia. These effects of Delta(9)-THC can be reduced in animal and human models of psychopathology by two...

Serotonin research: contributions to understanding psychoses

TIPS - Trends in Pharmacological Sciences August 1, 2008 Mark A. Geyer, Franz X. Vollenweider 435 citations

The history of serotonin research is closely related to the study of hallucinogenic drugs that function as agonists at serotonin-2A receptors. The fundamental idea that psychotic states seen in psychiatric disorders such as schizophrenia might be attributable, in part, to abnormalities in serotonergic systems began with the almost simultaneous discovery of lysergic acid diethylamide (LSD),...

Investigation of serotonin-1A receptor function in the human psychopharmacology of MDMA

Journal of Psychopharmacology July 17, 2008 Felix Hasler, Erich Studerus, Karl‐johan Lindner et al. 53 citations

Serotonin (5-HT) release is the primary pharmacological mechanism of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) action in the primate brain. Dopamine release and direct stimulation of dopamine D2 and serotonin 5-HT 2A receptors also contributes to the overall action of MDMA. The role of 5-HT 1A receptors in the human psychopharmacology of MDMA, however, has not yet been elucidated. In...

Effects of varied doses of psilocybin on time interval reproduction in human subjects

Neuroscience Letters February 13, 2008 Jiřı́ Wackermann, Marc Wittmann, Felix Hasler et al. 95 citations

Action of a hallucinogenic substance, psilocybin, on internal time representation was investigated in two double-blind, placebo-controlled studies: Experiment 1 with 12 subjects and graded doses, and Experiment 2 with 9 subjects and a very low dose. The task consisted in repeated reproductions of time intervals in the range from 1.5 to 5s. The effects were assessed by parameter kappa of the...

Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans

Psychopharmacology September 13, 2007 Olivia Carter, Felix Hasler, John D. Pettigrew et al. 150 citations

RationaleBinocular rivalry occurs when different images are simultaneously presented to each eye. During continual viewing of this stimulus, the observer will experience repeated switches between visual awareness of the two images. Previous studies have suggested that a slow rate of perceptual switching may be associated with clinical and drug-induced psychosis.ObjectivesThe objective of the...

The Effects of the Preferential 5-HT2A Agonist Psilocybin on Prepulse Inhibition of Startle in Healthy Human Volunteers Depend on Interstimulus Interval

Neuropsychopharmacology February 14, 2007 Franz X. Vollenweider, Philipp A Csomor, Bernhard Knappe et al. 194 citations

Schizophrenia patients exhibit impairments in prepulse inhibition (PPI) of the startle response. Hallucinogenic 5-HT(2A) receptor agonists are used for animal models of schizophrenia because they mimic some symptoms of schizophrenia in humans and induce PPI deficits in animals. Nevertheless, one report indicates that the 5-HT(2A) receptor agonist psilocybin increases PPI in healthy humans....

DOI: 10.1038/sj.npp.1301324 (opens in new tab) Full text (opens in new tab) Psilocybin Prepulse inhibition Hallucinogen Interstimulus interval +7

Effects of psilocybin on time perception and temporal control of behaviour in humans

Journal of Psychopharmacology May 20, 2006 Marc Wittmann, Olivia Carter, Felix Hasler et al. 245 citations

Hallucinogenic psilocybin is known to alter the subjective experience of time. However, there is no study that systematically investigated objective measures of time perception under psilocybin. Therefore, we studied dose-dependent effects of the serotonin (5-HT) 2A/1A receptor agonist psilocybin (4-phosphoryloxy-N, N-dimethyltryptamine) on temporal processing, employing tasks of temporal...

DOI: 10.1177/0269881106065859 (opens in new tab) Psilocybin Time perception Cognition Hallucinogen +4

Using Psilocybin to Investigate the Relationship between Attention, Working Memory, and the Serotonin 1A and 2A Receptors

Journal of Cognitive Neuroscience October 1, 2005 Olivia Carter, David C. Burr, John D. Pettigrew et al. 236 citations

Abstract Increasing evidence suggests a link between attention, working memory, serotonin (5-HT), and prefrontal cortex activity. In an attempt to tease out the relationship between these elements, this study tested the effects of the hallucinogenic mixed 5-HT1A/2A receptor agonist psilocybin alone and after pretreatment with the 5-HT2A antagonist ketanserin. Eight healthy human volunteers were...

The P3 in ‘ecstasy’ polydrug users during response inhibition and execution

Journal of Psychopharmacology September 1, 2005 Alex Gamma, Daniel Brandeis, Ruven Brandeis et al. 36 citations

Substance abuse and associated externalizing disorders are characterized by behavioural disinhibition and low impulse control, with reduced neural inhibition postulated to be the common underlying brain mechanism. The P3 component of event-related potentials (ERPs) is a widely used neurophysiological measure thought to reflect inhibitory brain processes, but as yet has not been assessed in...

MDMA affects both error-rate dependent and independent aspects of decision-making in a two-choice prediction task

Journal of Psychopharmacology June 27, 2005 Franz X. Vollenweider, Matthias E. Liechti, Martin P. Paulus 24 citations

Decision-making, i.e. selecting an action from a number of alternatives when the outcome is uncertain, is a complex process that is important for everyday life. 3,4-Methylenedioxymethamphetamine (MDMA), also known as 'Ecstasy', is a widely used recreational drug that is known to increase serotonin (5-HT) and, to a lesser extent, dopamine (DA) in animals. This study examined whether MDMA alters...

Modulating the Rate and Rhythmicity of Perceptual Rivalry Alternations with the Mixed 5-HT2A and 5-HT1A Agonist Psilocybin

Neuropsychopharmacology January 26, 2005 Olivia Carter, John D. Pettigrew, Felix Hasler et al. 122 citations

Binocular rivalry occurs when different images are presented simultaneously to corresponding points within the left and right eyes. Under these conditions, the observer's perception will alternate between the two perceptual alternatives. Motivated by the reported link between the rate of perceptual alternations, symptoms of psychosis and an incidental observation that the rhythmicity of...

Psilocybin impairs high-level but not low-level motion perception

Neuroreport August 1, 2004 Olivia Carter, John D. Pettigrew, David C. Burr et al. 83 citations

The hallucinogenic serotonin(1A&2A) agonist psilocybin is known for its ability to induce illusions of motion in otherwise stationary objects or textured surfaces. This study investigated the effect of psilocybin on local and global motion processing in nine human volunteers. Using a forced choice direction of motion discrimination task we show that psilocybin selectively impairs coherence...

DOI: 10.1097/00001756-200408260-00023 (opens in new tab) Psilocybin Hallucinogen Illusion Motion perception +5

Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose?effect study

Psychopharmacology March 1, 2004 Felix Hasler, Ulrike Grimberg, Marco A. Benz et al. 458 citations

RationaleSerotonin (5-Hydroxytryptamine, 5-HT) receptors play an important role in perception, affect regulation and attention. Pharmacological challenge with the 5-HT(2A) agonist psilocybin (PY) is useful in studying the neurobiological basis of cognition and consciousness.ObjectiveInvestigation of dose-dependent effects of PY on psycho(patho)logical and physiological parameters.MethodsEight...

Halluzinogene, Amphetamine und Entactogene

Therapeutische Umschau June 1, 2003 Franz X. Vollenweider, M. F. I. Vollenweider-Scherpenhuyzen 3 citations

MDMA ("Ecstasy") and its analogues such as MDE and MDA are amphetamine derivatives reported to produce an altered state with emotional overtones. Since more than ten years, ecstasy is after cannabis the most frequently used recreational drug by young adults, particularly in the so-called techno-scene. However, according to a recent survey there is an increasing trend for a revival of classic...

Effects of the 5-HT2A Agonist Psilocybin on Mismatch Negativity Generation and AX-Continuous Performance Task: Implications for the Neuropharmacology of Cognitive Deficits in Schizophrenia

Neuropsychopharmacology 2003 Daniel Umbricht, Franz X. Vollenweider, Liselotte Schmid et al. 192 citations

Previously the NMDA (N-methyl-D-aspartate) receptor (NMDAR) antagonist ketamine was shown to disrupt generation of the auditory event-related potential (ERP) mismatch negativity (MMN) and the performance of an 'AX'-type continuous performance test (AX-CPT)--measures of auditory and visual context-dependent information processing--in a similar manner as observed in schizophrenia. This...

DOI: 10.1038/sj.npp.1300005 (opens in new tab) Full text (opens in new tab) Psilocybin Mismatch negativity Nmda receptor Schizophrenia object-oriented programming +5

Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man

Journal of Pharmaceutical and Biomedical Analysis August 26, 2002 Felix Hasler, Daniel Bourquin, Rudolf Brenneisen et al. 100 citations

In a clinical study eight volunteers received psilocybin (PY) in psychoactive oral doses of 212+/-25 microg/kg body weight. To investigate the elimination kinetics of psilocin (PI), the first metabolite of PY, urine was collected for 24 h and PI concentrations were determined by high-performance liquid chromatography with column switching and electrochemical detection (HPLC-ECD). Sample workup...

Acute Psychological and Neurophysiological Effects of MDMA in Humans

Journal of Psychoactive Drugs June 1, 2002 Franz X. Vollenweider, Matthias E. Liechti, Alex Gamma et al. 92 citations

Since the mid 1990s, MDMA has been increasingly used as a recreational drug called "Ecstasy" by young people in Europe and the United States. However, despite the widespread recreational use of Ecstasy, systematic data on the psychological and neurobiological effects of MDMA have been scant. To further our understanding of the mechanism of action of MDMA, the authors conducted several studies...

Brain mechanisms of hallucinogens and entactogens

Dialogues in Clinical Neuroscience December 31, 2001 Franz X. Vollenweider 127 citations

This review focuses on recent brain imaging and behavioral studies of sensory gating functions, which assess similarities between the effects of classic hallucinogens (eg, psilocybin), dissociative anesthetics (eg, ketamine), and entactogens (eg, 3,4-methylenedioxymethamphetamine [MDMA]) in humans. Serotonergic hallucinogens and psychotomimetic anesthetics produce overlapping psychotic...

Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies

Human Psychopharmacology: Clinical and Experimental December 1, 2001 Matthias E. Liechti, Franz X. Vollenweider 243 citations

Abstract In preclinical studies, 3,4‐methylenedioxymethamphetamine (MDMA, ‘Ecstasy’) has been shown to release serotonin (5‐HT), dopamine and norepinephrine. However, the role of these neurotransmitters and their corresponding receptor sites in mediating the subjective effects of MDMA has not yet been studied in humans. Therefore, we investigated the effects of three different neuroreceptor...

A systems model of altered consciousness: integrating natural and drug-induced psychoses.

Brain Research Bulletin November 15, 2001 Franz X. Vollenweider, Mark A. Geyer

Increasing evidence from neuroimaging and behavioral studies suggests that functional disturbances within cortico-striato-thalamic pathways are critical to psychotic symptom formation in drug-induced and possibly also naturally occurring psychoses. Recent basic and clinical research with psychotomimetic drugs, such as the N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, ketamine, and...